CEO William J. Meury received total reported compensation of approximately $32.1 million in 2025, which is elevated but reflects a mid-year hire with a large one-time sign-on performance award (a special grant requiring significant sustained stock price appreciation over six years) that inflates the single-year reported figure. Excluding that one-time sign-on grant, the ongoing annual compensation structure is more in line with peers, and critically, the pay mix is heavily performance-oriented: 60% of Mr. Meury's target equity value is in performance stock awards tied to relative total shareholder return, 20% in stock options (which only pay out if the stock price rises), and 20% in time-based restricted stock units, meaning approximately 80% of his equity is at-risk or performance-contingent. On the pay-for-performance alignment check, Incyte's 1-year stock return of +64.2% meaningfully outpaced the XBI (SPDR S&P Biotech ETF) benchmark return of +61.8% over the same period, and the company delivered strong 2025 commercial results (20% revenue growth, $4.35 billion in net sales). The company maintains a meaningful clawback policy compliant with Dodd-Frank requirements, robust stock ownership guidelines, and double-trigger change-in-control equity vesting provisions, all of which are positive governance features.

Non-audit fees (audit-related fees of $47,000 plus tax fees of $0) total $47,000 against audit fees of $3,868,000, a ratio of approximately 1.2% — well below the 50% threshold that would raise independence concerns. Ernst & Young is a Big 4 firm appropriate for a company of Incyte's size and complexity. Auditor tenure is not disclosed in the proxy, so the tenure trigger does not fire per policy. No material restatements are noted.